Topic: preclinical research
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
Roche owes its pipeline to the separation of its research and early development units gRED and pRED—and it won’t be consolidating them anytime soon.
XenoGesis and BioAscent plan to integrate their drug discovery offerings.
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
Concept Life Sciences bought Acquila Biomedical for its translational biology capabilities.
California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science work.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.
Erytech Pharma has formed a collaboration with Canada’s Queen’s University to advance its drug against the metabolic disorder arginase-1 deficiency.
InMed is enlisting Atera Labs to develop 3D human skin models to assess the efficacy of its lead candidate, a drug for epidermolysis bullosa.
LifeArc has set up a seed fund to invest in early preclinical projects that are overlooked because of the high risk of failure at that stage of R&D.